Bio News
Daewoong Pharmaceutical has been notified of a decision to grant a U.S. patent related to ionizable lipids, a core technology for mRNA delivery. The patent covers the foundational technology for the lipid nanoparticle (LNP) delivery platform “eTurna,” including an ionizable lipid structure that delivers therapeutic nucleic acid materials to target cells. After completing formal registration, Daewoong Pharmaceutical plans to secure ionizable lipid rights in the United States and support the out-licensing of its antiaging pipeline.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
